Fig. 1
Ebselen inhibits IMPA activity and reduces myo-inositol levels. (A) In the in vitro enzymatic assay of IMPA activity, a recombinant human inositol monophosphatase 1 (IMPA1) was treated with various concentrations of ebselen or LiCl. The amount of released phosphate was determined using a phosphate assay kit. IMPA1 activity was then normalized against an untreated control. (B) Additionally, the cells were treated with ebselen (25 µM) or LiCl (30 mM) for 2 days. Subsequently, the myo-inositol content in each sample (1 × 106 cells) was quantified using a myo-inositol assay kit. Differences between treated samples and the untreated control were compared pairwise using the independent samples t-test (*p ≤ 0.05; **p ≤ 0.01).
